EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Pluripotent Path to Immunotherapy

Mame P Diop, Sjoukje J C van der Stegen

Experimental Hematology · 2024-11 · 139 · 104648

DOI: 10.1016/j.exphem.2024.104648 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2024-11. Verfasst von Mame P Diop und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Immunotherapy, Adoptive. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 228 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapy (ACT) enhances the patient's own immune cells' ability to identify and eliminate cancer cells. Several immune cell types are currently being applied in autologous ACT, including T cells, natural killer (NK) cells, and macrophages. The cells' inherent antitumor capacity can be used, or they can be targeted toward tumor-associated antigen through expression of a chimeric antigen receptor (CAR). Although CAR-based ACT has achieved great results in hematologic malignancies, the accessibility of ACT is limited by the autologous nature of the therapy. Induced pluripotent stem cells (iPSCs) hold the potential to address this challenge, because they can provide an unlimited source for the in vitro generation of immune cells. Various immune subsets have been generated from iPSC for application in ACT, including several T-cell subsets (αβT cells, mucosal-associated invariant T cells, invariant NKT [iNKT] cells, and γδT cells), as well as NK cells, macrophages, and neutrophils. iPSC-derived αβT, NK, and iNKT cells are currently being tested in phase I clinical trials. The ability to perform (multiplexed) gene editing at the iPSC level and subsequent differentiation into effector populations not only expands the arsenal of ACT but allows for development of ACT utilizing cell types which cannot be efficiently obtained from peripheral blood or engineered and expanded in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsImmunotherapy, AdoptiveHumansAnimalsKiller Cells, NaturalReceptors, Chimeric Antigen

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: stegens@mskcc.org.

Zitieren

APA

Diop, M. P., & van der Stegen, S. J. C. (2024). The Pluripotent Path to Immunotherapy. Experimental Hematology, 139, 104648. https://doi.org/10.1016/j.exphem.2024.104648

Vancouver

Diop MP, van der Stegen SJC. The Pluripotent Path to Immunotherapy. Experimental Hematology. 2024;139:104648. doi:10.1016/j.exphem.2024.104648

BibTeX
@article{Diop2024,
  author = {Diop, Mame P and van der Stegen, Sjoukje J C},
  title = {The Pluripotent Path to Immunotherapy},
  journal = {Experimental Hematology},
  year = {2024},
  volume = {139},
  pages = {104648},
  doi = {10.1016/j.exphem.2024.104648}
}
Kostenlos starten →